Eterna TherapeuticsERNA
ERNA
About: Eterna Therapeutics Inc is a biopharmaceuticals company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Employees: 8
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
20% more funds holding
Funds holding: 20 [Q3] → 24 (+4) [Q4]
11.21% less ownership
Funds ownership: 13.15% [Q3] → 1.94% (-11.21%) [Q4]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
61% less capital invested
Capital invested by funds: $747K [Q3] → $292K (-$455K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ERNA.
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Eterna Therapeutics Hosts Successful Inaugural Meeting with Newly Formed Scientific Advisory Board to Advance Cell Therapy Pipeline
Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs Meeting addressed progress and strategic direction for company's induced mesenchymal stem cell (iMSC) therapy programs
Neutral
GlobeNewsWire
1 month ago
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
New data from proof-of-concept study provides roadmap for treatment of ovarian cancer.
Neutral
GlobeNewsWire
2 months ago
Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors
World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna's lead indication in ovarian cancer World-renowned researcher brings expertise in obstetrics and gynecology from Yale University to advance Eterna's lead indication in ovarian cancer
Neutral
GlobeNewsWire
3 months ago
Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing
CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) announced today that it has regained compliance with Nasdaq for continued listing and that its stock will continue to trade on The Nasdaq Stock Market.
Neutral
GlobeNewsWire
4 months ago
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) today announced the successful completion of a comprehensive financial restructuring of the Company with the aim to accelerate its developmental activities and long-term success.
Neutral
GlobeNewsWire
4 months ago
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
CAMBRIDGE, Mass., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”) and Factor Bioscience Limited (“Factor”) today announced an exclusive license and collaboration agreement aimed at accelerating the development of advanced cell therapy candidates for oncology, rare diseases, and autoimmune disorders. Under the terms of the agreement, Eterna has secured a worldwide, exclusive, non-transferable, royalty-bearing license, with the right to grant sublicenses, to develop and market certain induced pluripotent stem cell (iPSC)-based cell therapy products (in particular iPSC derived mesenchymal stem cells (iMSC) that are engineered to express certain cytokines) utilizing Factor's cell reprogramming and gene-editing technologies, patents, and know-how. The agreement positions both companies with the potential to accelerate the development of advanced cell therapies in the oncology, rare disease, and autoimmune fields.
Neutral
GlobeNewsWire
10 months ago
Eterna Therapeutics to Present at the ASGCT 27th Annual Meeting on Development of Beta 2 Microglobulin-Knockout (B2M-KO) iMSC Line with Enhanced Immunosuppressive Activity and Stealthing Features that May Further Augment the Therapeutic Potential of MSCs in Inflammatory Diseases
The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells The presentation is on Saturday, May 11th, 2024 CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a biopharmaceutical company using advanced cell engineering technology to develop transformational new medicines, today announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene + Cell Therapy, taking place in Baltimore, Maryland.
Neutral
GlobeNewsWire
10 months ago
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
CAMBRIDGE, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA ) (“Eterna” or the “Company”), a preclinical-stage biopharmaceutical company, committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announces the appointment of Mahendra Rao, PhD, to its scientific advisory board.
Neutral
GlobeNewsWire
1 year ago
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the appointment of Peter Cicala, JD, to its Board of Directors.
Neutral
GlobeNewsWire
1 year ago
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced that Eterna's Board of Directors granted a non-qualified stock option to purchase 1,685,218 shares of Eterna's common stock (the “Stock Option”) to its new President and Chief Executive Officer, Sanjeev Luther, effective January 1, 2024, the first date of his employment. The Stock Option was granted pursuant to the terms of Mr. Luther's employment agreement and as a material inducement to his joining Eterna as President and Chief Executive Officer in accordance with Nasdaq Listing Rule 5635(c)(4).
Charts implemented using Lightweight Charts™